乳腺癌术后随机分组辅助放疗15年疗效观察

目的　探讨乳腺癌术后辅助放疗的远期疗效。方法　 16 2例手术后乳腺癌随机分为放疗组与对照组。放疗组照射锁骨上区和 (或 )内乳区各 5 0Gy,对照组不放疗。按临床分期、肿瘤部位及腋淋巴结有无转移比较两组生存差异。结果　 5 ,10 ,15年生存率放疗组分别为 72 .0 %、5 6 .1%和5 4 .3% ,对照组分别为 6 6 .3%、5 1.3%和 4 9.4 % ,两组差异无显著性 (P >0 .0 5 )。按临床Ⅰ～Ⅲa期、腋淋巴结 (+)或 (- )比较 ,除腋淋巴结 (+)≥ 4外 ,两组差异均无显著性。在腋淋巴结 (+)≥ 4时 ,放疗组 5 ,10 ,15年生存率分别为 5 5 .6 %、38.9%和 37.1% ,对照组分别为 2 9.0 %、16 .1%和 16 .1% ,放疗组疗效有明显提高 (P <0 .0 5 )。结论　乳腺癌术后放疗对腋淋巴结 (- )患者未能改善预后 ,对腋淋巴结 (+)≥ 4个者有益。

Randomized trial on adjuvant radiotherapy for postoperative breast cancer: a 15 year experience

OBJECTIVE: To evaluate the long term effects of adjuvant radiotherapy for postoperative breast cancer. METHODS: From 1985 to 1986, 162 patients with operable breast cancer were randomly given adjuvant radiotherapy according to clinical stage and involving condition of axillary lymph nodes (LN). The radiotherapy group (RG) was irradiated in the supraclavicular area and/or internal mammary area to 50 Gy, while the control group (CG) was not. RESULTS: The overall 5-, 10- and 15-year survival rates of the RG were 72.0%, 56.1% and 54.3%, while they were 66.3%, 51.3% and 49.4% in the CG (P > 0.05). Clinical stage I-IIIa and positive or negative LN showed no significant difference in the two groups. But in patients with LN(+) > or = 4, the 5-, 10- and 15-year survival rates of the RG were 55.6%, 38.9% and 37.1%, which were higher than the CG of 29.0%, 16.1% and 16.1% (P < 0.05). CONCLUSION: Adjuvant radiotherapy can improve the prognosis for breast cancer patients with LN(+) > or = 4, but not for LN(-).